About Orexo
Orexo is a publicly listed company based in Uppsala (Sweden) founded in 1995. It operates as a therapeutics for mental illness and substance use disorders are developed. Orexo has completed 2 acquisitions, including BioLipox and PharmaKodex. Its chief executive is Nikolaj Sorensen. Orexo offers products and services including AmorphOX and OX640. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is Orexo AB (publ.). Its competitors include Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals and 5 more; 7 of its 10 listed competitors have raised funding.
Company details
Orexo was founded in 1995 in Uppsala, Sweden, and operates in the pharmaceutical sector. Therapeutics targeting mental illness and substance use disorders, including opioid use disorder and related conditions, are developed using proprietary formulation technologies. Treatment solutions are created to address unmet medical needs in these areas, with a focus on patient outcomes through innovative drug delivery methods.
- Annual Revenue$2.82 M (USD)-12.46as on Dec 31, 2025
- Net Profit-$14.09 M (USD)36.06as on Dec 31, 2025
- EBITDA-$30.39 M (USD)6.86as on Dec 31, 2025
- Investments & AcquisitionsBioLipox
& 1 more
Products & Services of Orexo
Orexo offers a comprehensive portfolio of products and services, including AmorphOX and OX640.
Advanced powder technology for developing new medications.
Epinephrine treatment for allergic reactions and emergencies.
Apps and channels of Orexo
its YouTube channel Orexo has 49 subscribers and 30 videos.
Videos from Orexo
The most watched videos on Orexo's YouTube channel, Orexo (49 subscribers). Click a video to play it here.
More on Orexo.
People of Orexo
43 people are tracked at Orexo (12 in leadership, 8 in board & advisors, 23 in team).
| Name | Role | Group |
|---|---|---|
Nikolaj Sorensen | CEO | Leadership |
Nikolaj Sørensen | President and CEO | Leadership |
Salem Tewolde | Head Of Supply Chain | Leadership |
Edward Kim M.D. | Chief Medical Officer | Leadership |
Greta Kampe | Director Business Development | Leadership |
Mark Michael Pharmd, Rph | Associate Director, Medical Affairs | Leadership |
Cecilia Coupland | Senior Vice President, Head Of Operations | Leadership |
Rich Murphy | Senior Vice President Market Access, Government Affairs & Marketing | Leadership |
Robert Coburn (Boz) | Head Of Business Development | Leadership |
Janne Laine | Vice President Group Finance | Leadership |
Maria Wangelin | Head Of Quality & SHE | Leadership |
Zillur Rahman | Executive Assistant To The CEO And Office Manager | Leadership |
James Noble | Chairman | Board & advisors |
Fred Wilkinson | Board member | Board & advisors |
Mary Pat Christie | Board member | Board & advisors |
Staffan Lindstrand | Board member | Board & advisors |
Henrik Kjaer Hansen | Board member | Board & advisors |
David Colpman | Board member | Board & advisors |
Charlotte Hansson | Board Member | Board & advisors |
Kirsten Detrick | Board member | Board & advisors |
23 more people are available in the full profile.
Complete people profiles for Orexo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Orexo
Orexo is a publicly listed company on the OMXSTO with ticker symbol ORX in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Nov 2005
- Listed onOMXSTO: ORX
- Listed entityOrexo AB
- Exchange sectorHealth technology
- ISINSE0000736415
- Share price6.27 SEK (+2.79% on the day) · 2026-10-14
- Market capitalisation213,022,038.00 SEK
- EPS (diluted, trailing year)-8.81 SEK
- Volume (last session)23,330
Financials of Orexo
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 26.0M SEK | -129.8M SEK | -279.9M SEK |
| 2024 | 29.7M SEK | -203.0M SEK | -300.5M SEK |
| 2023 | 638.8M SEK | -128.3M SEK | -45.6M SEK |
| 2022 | 624.3M SEK | -177.6M SEK | -128.8M SEK |
| 2021 | 565.0M SEK | -223.5M SEK | -165.1M SEK |
Detailed financial statements for Orexo
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orexo
Orexo has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BioLipox and PharmaKodex.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Proprietary drug delivery technologies are developed for medicine reformulation. | pharmakodex.com | Chippenham, United Kingdom | 2006 | Feb 2009 | •••• | |
Arachidonic acid-based drugs are developed for respiratory and inflammatory diseases. | biolipox.com | Solna, Sweden | 2000 | Oct 2007 | $133.11M |
Complete acquisition details for Orexo
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Orexo
4 dated milestones of Orexo across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Orexo is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires BioLipox.
- Acquisition Acquires PharmaKodex.
Competitors of Orexo
Orexo has 10 listed competitors in our database, 7 of them funded. They include Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| biotie.com | 1998 | Turku, Finland | $149.81M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| opiant.com | 2005 | Santa Monica, United States | – | 31 | Therapeutics for addictive and eating disorders are developed. | |
| amygns.com | 2015 | San Francisco, United States | $7.05M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| 4p-pharma.com | 2014 | Lille, France | $18.49M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.04M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases |
Detailed competitors of Orexo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Orexo
The website of Orexo (orexo.com) receives about 5.2K visits a month.
- Monthly visits5.2K
▲ 477.2% vs previous month
Websites whose visitors overlap most with Orexo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| getingegroup.com | 100% | – | – | View details | |
| gsk.com | 87% | 1.3M | #56,834 | View details | |
zubsolv.com | zubsolv.com | 86% | – | #1,315,008 | – |
| pdr.net | 75% | 118.1K | #357,511 | View details | |
| sca.com | 70% | 87.8K | #423,151 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Orexo
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
10 companies that operate in the same segment as Orexo (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orexo
Complete news archive for Orexo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orexo
Orexo was founded in 1995.
Orexo is headquartered in Uppsala, Sweden. It is registered at Uppsala, Uppsala County, Sweden.
Nikolaj Sorensen is the current CEO of Orexo.
Annual revenue of Orexo is $2.82M as on Dec 31, 2025.
Orexo was founded in 1995 in Uppsala, Sweden, and operates in the pharmaceutical sector. Therapeutics targeting mental illness and substance use disorders, including opioid use disorder and related conditions, are developed using proprietary formulation technologies. Treatment solutions are created to address unmet medical needs in these areas, with a focus on patient outcomes through innovative drug delivery methods.
Orexo's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
Orexo offers AmorphOX and OX640.
Yes, Orexo is publicly traded on OMXSTO under the ticker symbol ORX.
Orexo has made 2 acquisitions, including BioLipox, and PharmaKodex.
Orexo operates through Orexo Ab (Publ.).